Shares of Smith & Nephew plc (NYSE:SNN) have received an average rating of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $27.50.
A number of equities analysts have recently weighed in on the stock. Zacks Investment Research cut shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Canaccord Genuity set a $23.00 price target on shares of Zymeworks and gave the stock a “buy” rating in a research note on Friday, May 3rd.
Shares of NYSE:SNN traded down $0.37 on Tuesday, reaching $43.45. 304,966 shares of the company were exchanged, compared to its average volume of 353,246. The company has a current ratio of 2.10, a quick ratio of 1.15 and a debt-to-equity ratio of 0.27. Smith & Nephew has a 1-year low of $32.22 and a 1-year high of $44.55. The company has a market capitalization of $19.00 billion, a price-to-earnings ratio of 21.51, a price-to-earnings-growth ratio of 3.18 and a beta of 0.28. The stock’s 50-day simple moving average is $43.12.
Hedge funds and other institutional investors have recently modified their holdings of the stock. First Trust Advisors LP purchased a new stake in Smith & Nephew in the 4th quarter worth $201,000. LPL Financial LLC lifted its stake in Smith & Nephew by 12.3% in the 4th quarter. LPL Financial LLC now owns 18,625 shares of the medical equipment provider’s stock worth $696,000 after purchasing an additional 2,037 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Smith & Nephew in the 4th quarter worth $57,000. New York State Common Retirement Fund lifted its stake in Smith & Nephew by 305.8% in the 4th quarter. New York State Common Retirement Fund now owns 194,402 shares of the medical equipment provider’s stock worth $7,267,000 after purchasing an additional 146,502 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Smith & Nephew by 4.5% in the 4th quarter. Bank of New York Mellon Corp now owns 79,606 shares of the medical equipment provider’s stock worth $2,975,000 after purchasing an additional 3,422 shares in the last quarter. 8.69% of the stock is currently owned by hedge funds and other institutional investors.
Smith & Nephew Company Profile
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
See Also: What is the Current Ratio?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.